Tag Archive for: cdmo

For biotechnology companies developing and marketing advanced treatments like CAR-T cell therapies, clinical success is only half the battle. The ultimate operational test is managing the clinical clock, which starts ticking the moment a patient’s cells are collected. For autologous cell therapy CDMOs, managing the total time from the initial cell collection to the infusion back into the patient, or vein-to-vein (V2V) time, is one of the primary keys to success.

Currently, the most significant bottleneck in the V2V cycle is quality control (QC) and lot release processes, as traditional quality and lot release tests routinely take weeks to complete, an unacceptable duration when most cell therapy patients are critically ill and cannot wait for treatment, not to mention the challenges in maintaining cell viability. 

Cell therapy lot release is the critical quality assurance process that verifies a cell therapy is safe, sterile, and potent before it is administered. For autologous therapies, it serves as the final gatekeeper to ensure that a treatment meets predefined specifications, preventing the administration of failed or harmful doses.

As mentioned, accelerating lot release is vital and by modernizing testing workflows, cell therapy developers can safely slash V2V times, reduce manufacturing costs, and deliver treatments to bedsides faster. Here are four ways cell therapy CDMOs can accelerate cell therapy lot release. 

1. Leverage Rapid Microbiological Methods (RMM)

Traditional sterility tests rely on legacy growth-based methods that require growing microbes in culture dishes to determine whether contamination is present. This process is slow, requiring 14 to 28 days to yield a final, compliant result. For autologous cell therapies, where a single batch of medicine is custom-made for a specific patient, 14 days can easily consume the product’s entire viable shelf life, not to mention the clinical need to rapidly receive the therapeutic for patient treatment.

Utilizing RMMs can include benefits such as:

  • Automated Systems: Growth-based automated platforms detect microbial contamination days earlier by continuously monitoring changes in the sample.
  • Molecular Tests: Modern techniques like Polymerase Chain Reaction (PCR) copy target DNA to identify hidden mycoplasma bacteria in just hours instead of weeks.
  • Rapid Cartridges: For endotoxin testing, cartridge-based automated tools compress testing windows to under 15 minutes.

Adopting these rapid safety testing tools can shave weeks off the lot release timeline, ensuring patients receive healthy cells and keeping their treatment programs on track.

2. Automate Analytics and Data Gating

Manual quality control testing introduces human error, high operator-to-operator variability, and massive data bottlenecks. Automating these analytical workflows removes human variables and standardizes data collection. Options from this automation can include solutions such as:

  • Smart Instruments: Instruments such as modern, high-throughput flow cytometers feature premixed test reagents and automated gating software to generate operator-independent results in minutes.
  • Multiplexing: Advanced automated immunoassay platforms enable QC teams to simultaneously analyze a therapeutic lot for multiple quality parameters, such as cell identity, viability, purity, and potency, from a single sample.

These approaches both expedite quality control testing and conserve sample material. For autologous therapies, patient material is limited and time is of the essence, making automation and advanced methods even more important.

3. Transition to Real-Time Release Testing (RRT)

A traditional pharmaceutical manufacturing model treats cell production and quality testing as separate, sequential phases. However, real-time release testing (RRT) removes this barrier by integrating manufacturing and testing.

By incorporating process analytical technologies (PAT) to monitor cells as they grow and by creating closed manufacturing systems, operators can continuously check medicine quality. Some approaches to achieve RRT include:

  • Enclosed Platforms: Fully enclosed manufacturing platforms perform automated in-process checks, cell washing, and final formulation without exposing cells to external elements.
  • Digital Connectivity: Connecting process instruments to digital manufacturing execution systems (MES) and laboratory information management systems (LIMS) enables real-time data transmission, supporting RTT.

Quality assurance teams can review data during the manufacturing run rather than after the batch is finished. The shift to RRT drastically reduces delays in final batch release and boosts facility throughput.

4. Leverage Regulatory Flexibilities and CMC Guidance

The FDA and other global regulators fully recognize that new rules are needed for living, personalized medicines. In response, they have introduced specific chemistry, manufacturing, and controls (CMC) flexibilities designed specifically for the cell therapy sector. Biotech executives and CDMOs can leverage these evolving guidelines to streamline their lot release programs significantly.

  • Smart Evaluation: Modern guidelines allow grouping strategies such as bracketing and matrixing that reduce the total number of validation lots a company must test.
  • Conditional Release: Agencies permit conditional protocols for ultra-short-shelf-life products, meaning a manufacturer can safely ship a product to the hospital for infusion while longer-term, traditional sterility tests finish incubating in the background.

Engaging early with regulators to secure approval for these flexible analytical strategies reduces potential approval complications and paves the way for a clear pathway to the market.

Kincell Bio’s RTP Facility Expansion is Expediting Lot Release and Expanding QC Testing Capacity

Reducing vein-to-vein time requires a multi-prong strategy, and modernizing lot release is critical to the effort. By adopting rapid microbiological methods, automating analytical steps, shifting toward real-time testing data, and embracing regulatory flexibilities, companies can safely and dramatically reduce their production timelines. Every day saved in the quality control laboratory is a day given back to a patient waiting in a hospital.

To meet this need, Kincell Bio is making significant investments to expand the Research Triangle Park, North Carolina, facility. As part of this effort, we are converting existing space into a dedicated microbiology lab, which will allow us to bring rapid microbial and sterility testing fully in-house, eliminating dependence on outsourcing and accelerating release timelines. The expansion also includes an additional quality lab to increase testing capacity.

Contact us to learn more about how our Research Triangle Park expansion is supporting the expedited release of lots for autologous and allogeneic cell therapies.

Combination creates a scaled U.S. advanced therapies CDMO with broader technical expertise and capabilities from early development through commercial supply.

RESEARCH TRIANGLE PARK, NC and THE WOODLANDS, TX —  Sept. 17, 2026: Kincell Bio and Cellipont Bioservices today announced the completion of their merger to form Kincellis Advanced Therapies (Kincellis), a U.S.-based contract development and manufacturing organization focused on cell therapies and other advanced modalities.

Kincellis Advanced Therapies brings together Kincell’s depth in immune-cell technologies with Cellipont’s experience across stem cells, iPSCs, MSCs, dendritic cells, exosomes and emerging mRNA-enabled approaches. This combined scientific breadth enables Kincellis to support autologous and allogeneic therapies across a wide range of cell types and modalities — from early development through commercial supply — giving customers access to deeper technical expertise and more comprehensive solutions within one organization.

Together, the two companies have released more than 150 GMP batches for clients and are supporting 10 IND filings this year alone, experience that reflects not only scale, but a shared commitment to helping promising therapies reach patients.

Darren Head serves as CEO of Kincellis and brings an outstanding track record of building advanced therapies CDMOs over the last two decades. “Kincell and Cellipont are highly complementary in their science, facilities and the stages of development they serve. Together, we can offer customers broader expertise and a more connected path from process and analytical development through late-stage manufacturing, while maintaining the responsiveness and hands-on partnership that are essential in cell therapy,” said Darren Head, Chief Executive Officer, Kincellis Advanced Therapies.

Kincellis operates approximately 140,000 square feet of development and manufacturing infrastructure across Gainesville, Florida; Research Triangle Park, North Carolina; and The Woodlands, Texas. The combined network includes 16 operational, qualified GMP manufacturing suites supporting programs from early development and clinical manufacturing through pivotal and commercial supply.

The three-site network provides customers with greater flexibility, capacity and continuity as programs advance, while enabling Kincellis to align programs with the technical teams and manufacturing capabilities best suited to their development stage and supply needs. The experienced operations team, comprising leaders from both organizations and more than 200 dedicated team members, will be led by Larry Pitcher, President of Kincellis Advanced Therapies, who said “Our priorities are clear: maintain continuity for every customer, connect the strongest capabilities of both organizations and build a common platform that can scale with customer needs. This combination creates meaningful opportunities for our customers, our teams and the advanced-therapies industry.”

The company will be supported by an experienced Board led by Mark Bamforth OBE, as Executive Chair, who said “Kincellis brings together the expertise, infrastructure and experience needed to support advanced-therapy innovators as their programs grow from the clinic toward commercial supply. We are creating a stronger, more scalable partner built around the realities of advanced-therapy development and supply.”

The equity financing for the transaction was led by NewSpring Capital with support from existing investors Kineticos Life Sciences, HealthQuest Capital and Great Point Partners, together with a debt facility provided by J.P. Morgan. William Blair & Company served as financial advisor to Cellipont Bioservices. Financial terms were not disclosed.

About Kincellis Advanced Therapies

Kincellis Advanced Therapies is a U.S.-based contract development and manufacturing organization supporting advanced-therapy developers from early-stage CMC, process and analytical development through clinical supply, pivotal-stage programs and commercial supply. With facilities in Gainesville, Florida; Research Triangle Park, North Carolina; and The Woodlands, Texas, Kincellis combines broad technical expertise with flexible, scalable GMP infrastructure across autologous and allogeneic therapies, including but not limited to CAR-T, Tregs, CAR-NK, MSCs, dendritic cell vaccines, exosomes, iPSCs & synthetic mRNA. Visit our website at www.Kincellis.com  

Media Contact

Edwin Beale
CCO / Kincellis Advanced Therapies
Info@Kincellis.com
+1 302-379-1304

In this exclusive Cell & Gene Therapy Review feature, Darren Head, CEO, and Larry Pitcher, President, share how the combination of Kincell Bio and Cellipont Bioservices came together; and what it means for customers, employees, and the future of the organization.

The conversation explores the complementary science and capabilities behind the merger, plans for continued growth, and an important priority as Kincellis scales: preserving the agility, personalized service, and customer-focused culture of both organizations.

Read the Full Story

Cell therapy development is defined by a fundamental tension: the pressure to move fast and the imperative to get it right. With many programs receiving expedited approval designations, the need to reach the clinic quickly is real, but so are the consequences of cutting corners on analytical rigor. The programs that navigate this tension most successfully are those that build analytical strategies without over-engineering in early development, as that will add time and costs, yet remain focused on later development phases and, ultimately, on commercialization.

Analytical development is not simply a technical function. It is the informational backbone of an entire cell therapy program. Robust assay development enables accurate and precise assessment of critical process parameters and product quality attributes, ensuring therapeutic product consistency, safety, and effectiveness. When analytical strategies are built with long-term commercialization in mind from day one, they simplify decision-making, reduce risk, and align early development with the regulatory expectations that will ultimately determine whether a therapy reaches patients.

Why Early Investment in Analytics Is Non-Negotiable

Phase-appropriate method development does not mean taking shortcuts, as every early decision shapes the trajectory of a program from research to commercialization. However, well-constructed analytics are the foundation of any cell therapy program because, without trustworthy data, informed and defensible process changes based on additional learning simply cannot be made.

Under the pressure of expedited timelines and tight budgets, the temptation to defer implementation of system-suitability controls and method qualification is understandable. The consequences, however, are severe, as when analytical methods are unreliable, every downstream decision is built on an unstable foundation. Critical parameters drift from loosely defined lab values to poorly controlled GMP targets; quality teams lose the ability to defend product release criteria; and the gap between early development and commercial requirements widens with each passing phase. What begins as a shortcut compounds into costly method redevelopment, comparability studies, and IND revisions, each one consuming the time and resources that were supposedly being saved.

Investing early in robust analytical methods and a clear CMC roadmap allows teams to anticipate and mitigate risks while maintaining the flexibility to adapt as knowledge deepens. It also avoids common assay qualification weaknesses, including a lack of specificity, concerns about reproducibility, and poorly defined acceptance criteria, all of which are frequent sources of regulatory questions and clinical delays.

The DoE Advantage

For cell therapy programs, where complex, interacting process parameters can significantly impact critical quality attributes, the traditional approach of exploring one variable at a time is neither efficient nor sufficient. A Design of Experiments (DoE) approach fundamentally changes the equation.

Rather than sequential variable exploration, DoE studies enable simultaneous assessment of multiple parameters, dramatically increasing resource efficiency and reducing the time and cost required for analytical method development. For cell therapies, critical quality attributes such as cell population purity and identity are influenced by a wide range of process variables, including multiplicity of infection, cytokine concentrations, and expansion duration. Understanding how these parameters interact and affect the target product profile requires the multidimensional insight that only DoE can reliably provide.

In practice, DoE studies performed using material from a single donor generate the data needed to evaluate the impact of multiple process parameters while minimizing upfront experimentation. Large-scale confirmation runs using optimized conditions can then be performed across numerous donors to validate the defined process design space and analytical assays. The result is a comprehensive analytical control strategy, encompassing both release and characterization tests, that reduces variability in the starting material while laying the foundation for a robust IND-enabling package.

Stage Gates and Phase-Appropriate Control

A sound analytical strategy is not a one-time decision. It is a discipline sustained across the entire development lifecycle through structured milestones and stage gates. Approaching development this way allows teams to define mitigation strategies proactively, as part of the product development lifecycle rather than in response to emerging problems. The payoff is simplified decision-making, proactive risk management, and continuous alignment of early development with commercial goals.

Analytical methods should be refined and optimized with each clinical batch, aligned with critical quality attributes and process parameters, and progressively prepared for method validation in accordance with ICH guidelines. A phase-appropriate analytical control strategy allows developers to ensure product quality at each stage, begin understanding patient variability within the trial framework, and establish a credible path into the clinical setting. 

As programs mature, characterization insights become increasingly valuable. Early development release assays focused on identity, purity, potency, and safety are essential but rarely sufficient on their own. Investment in deeper characterization assays, covering phenotype, metabolomics, transcriptomics, and additional potency assessments, builds the product knowledge needed to support future regulatory submissions and comparability studies. Over time, the most informative of these assays are elevated from characterization to release tests as data accumulates and specifications can be established. Other key actions in this maturation process include tightening specifications as manufacturing history grows, establishing reference standards for commercial production, and developing a coherent potency assurance strategy aligned with FDA guidance.

Kincell Bio’s Science-First Approach

Risk management in cell therapy development is not about avoiding ambition; it is about creating the strongest possible foundation for success. By leveraging early investment in analytics, combined with a DoE approach, stage gates, and deep scientific expertise, innovators can confidently navigate the complexities of process and analytical method development and deliver high-quality, transformative therapies to patients.

Analytical strategy is never an afterthought for Kincell Bio’s team. Our science-first mindset means we invest early in robust method development, creating assays that validate critical quality attributes within data-driven frameworks and evolve as programs advance. Our early-stage analytical strategies encompass system-suitability controls and method qualification; an emphasis on precision and accuracy for foundational methods such as cell count and viability; and potency and characterization matrices aligned with the mechanism of action, connecting quality with biology, supporting comparability, and building regulatory confidence for IND submissions. For allogeneic programs, we integrate donor qualification and correlation of donor attributes with potency and clinical outcomes, recognizing that the uniqueness of each cell therapy demands a tailored approach to assay development.

The analytical strategies we establish at Kincell Bio do not simply meet regulatory expectations; we ensure each phase of clinical development is supported by the appropriate level of product and process characterization, and that our clients’ programs are equipped to advance safely, scalably, and compliantly from early development through to commercialization.

To discuss how Kincell Bio would approach analytical challenges specific to your program, please contact us.

As cell therapies advance from early development toward commercialization, Chemistry, Manufacturing, and Controls (CMC) strategy has become a critical determinant of regulatory and clinical success. A proactive, evolving CMC roadmap can help sponsors anticipate regulatory expectations, reduce manufacturing risk, and avoid costly delays throughout development.

In this featured article published by Cell & Gene Therapy Review, Roger Herr, PhD, explores the most common CMC pitfalls facing today’s cell therapy developers and shares practical strategies for building a dynamic roadmap that supports scalable manufacturing, regulatory readiness, and long-term program success.

Whether you’re preparing for your first IND or planning for commercial manufacturing, this article provides valuable insights into developing a robust CMC strategy that helps keep your program on track.

Read the full article to learn how early CMC planning can help accelerate development while minimizing regulatory and manufacturing risk.

Read the Full Article

While the curative potential of cell therapies is incredible, the path from a promising candidate in the lab to an approved therapy in the clinic is extraordinarily complex. However, the majority of programs that complete the journey successfully share one thing in common: they planned for commercial success from the very beginning.

At the center of that planning is a Chemistry, Manufacturing, and Controls (CMC) roadmap. More than a regulatory document, an effective CMC roadmap is a strategic framework that guides every critical decision across a cell therapy program’s lifecycle. It anticipates risks before they become crises, aligns process and analytical development with long-term commercialization goals, and ensures that every milestone is built on a foundation strong enough to support the next phase.

Elements of an Effective CMC Roadmap

A results-driven CMC roadmap does several things simultaneously. It delineates IND and BLA timelines, including submission milestones, provides a cost overview, and evolves as the program advances from early- to late-phase clinical development and ultimately to commercialization. It is not a static document; rather, it is a living strategy that matures alongside the therapy it supports.

Building a successful CMC roadmap begins with defining the target product profile, or TPP. Understanding the therapeutic indication and patient population, clinical efficacy goals, safety profile, route of administration, dosage, quality requirements, formulation, and storage and transportation needs ensures that the critical quality attributes selected genuinely reflect and support clinical performance expectations. From there, the best analytical methods to robustly link those attributes to the TPP must be identified to enable more informed decision-making and help developers avoid the costly delays caused by rework and comparability studies later in development.

Risk identification and mitigation must be woven throughout the roadmap from the outset. The highest risks in cell therapy development typically relate to manufacturability, variability in raw materials, variability in cell sources, and insufficient early process characterization. Early-stage decisions directly impact the feasibility of scaling to commercial production, which is why manufacturability assessments early in the CMC roadmap are essential as they flag potential scaling bottlenecks and other challenges before they become existential threats. Evaluating the availability of key reagents and donor material, and establishing clear approaches to chain of identity and chain of custody for patient-derived material, allows teams to develop supply chain, donor screening, and process development strategies that manage risk proactively rather than reactively.

Engaging regulators early through pre-IND meetings is one of the most effective risk-reduction tools available to cell therapy developers. These conversations give sponsors the opportunity to validate their CMC strategy before committing significant resources, secure regulatory alignment on key analytical and manufacturing decisions, and surface any concerns around raw material sourcing, comparability protocols, or assay qualification approaches while there is still room to course-correct. Equally important, they allow both parties to establish shared expectations and concrete phase-based milestones,  bringing structure and predictability to the development process. For programs operating under expedited timelines, this clarity is not a luxury; it is a competitive advantage.

Stage Gates: Structured Decision-Making Across the Development Lifecycle

Risk management in cell therapy development is not a single event. It is a discipline sustained across every phase through structured milestones and stage gates. Approaching development as a series of milestones, with mitigation strategies defined as part of the product development lifecycle, enables teams to simplify decision-making, proactively address uncertainties, and continuously align early development with long-term commercialization goals.

Stage gates allow for careful evaluation of cost, time, and quality tradeoffs at each critical juncture, ensuring that decisions are thoughtful and grounded in data rather than made under pressure. Tools such as well-designed Design of Experiments (DoE) studies, phase-appropriate analytical control strategies, and careful evaluations of sequential versus parallel processes streamline early development and ensure smoother transitions through each stage.

Characterization is equally important in this framework and should be considered no less critical than release testing. Investing in characterization assays that interrogate aspects of the product beyond those explicitly required for regulatory compliance deepens process understanding, informs relevant risk assessments, and ensures that specifications taken into late-stage development are genuinely appropriate for the product.

Building the Roadmap with the Right Partner

Success requires sufficient expertise across cell therapy process scaling, raw material sourcing, process and analytical development, GMP manufacturing, and regulatory compliance. When built correctly and supported by the right partner, a CMC roadmap accelerates a program, ensures high product quality, future-proofs regulatory submissions, and minimizes costly surprises.

At Kincell Bio, CMC roadmap development begins by mapping critical quality attributes and designing robust manufacturing processes well in advance of pivotal trials, and integrating process science, quality systems, and regulatory strategy from day one. By front-loading this work, we not only expedite the submission review process but also help clients avoid the costly facility retrofits and process overhauls.

The CMC roadmaps Kincell Bio builds with its clients establish clear, practical paths for the consistent manufacturing of cell therapy candidates that meet safety, identity, quality, purity, and potency standards, while saving time, reducing costs, and reducing risk at every stage of development. To discuss how Kincell Bio would build a CMC roadmap for your program, please contact us.

Why analytical development is one of the most important and often overlooked foundations of a successful cell therapy program.

As cell therapies advance from discovery through clinical development and commercialization, analytical development plays a critical role in ensuring product quality, process understanding, regulatory readiness, and long-term manufacturing success.

In this article published by Contract Pharma, Roger Herr, PhD, Director, Analytical Development, and Patrick Kellish, PhD, Senior Scientist, Analytical Development at Kincell Bio, explore why analytical strategies should be established early and how a robust analytical framework can help developers navigate variability, support comparability, and build scalable cell therapy processes.

Read the full article to learn how a science-driven approach to analytical development can help set cell therapy programs up for success from the start.

Read the Article

Multi-million-dollar investment in facility infrastructure, quality management, and enterprise systems positions Kincell Bio to support an increasing number of clients preparing for commercialization and to meet growing market demand in the cell therapy sector.

Research Triangle Park, NC — April 14, 2026 — Kincell Bio, a leading contract development and manufacturing organization (CDMO) supporting autologous and allogeneic cell therapy programs, today announced a significant strategic investment to expand and strengthen its Research Triangle Park (RTP), North Carolina, facility. The expansion reinforces Kincell Bio’s commitment to supporting clients as they advance from late-stage clinical CMC development through commercialization and post-approval life cycle management.

Expanding Capacity to Meet the Demands of a Maturing Industry

The RTP facility serves as Kincell Bio’s center of excellence for pivotal supply, commercialization, and commercial manufacturing, complementing its early-phase focused facility in Gainesville, Florida. The RTP site currently houses four ISO 7 cleanroom suites, and the expansion will enable the addition of two more suites, meaningfully increasing the facility’s capacity to support both autologous and allogeneic cell therapy programs at commercial scale.

“This expansion reflects our commitment to supporting our clients’ commercial success and our confidence in the trajectory of the overall cell therapy industry,” commented Larry Pitcher, Chief Executive Officer of Kincell Bio. “A number of our clients are preparing for commercialization, and these investments will ensure that our infrastructure is ready to support them at every stage of that journey.”

The build-out includes a comprehensive suite of supporting infrastructure designed to meet the rigorous demands of late-stage and commercial programs:

  • Additional QC Laboratory to support expanded quality control testing across a growing client portfolio
  • MSAT/ASAT Laboratory purpose-built to support later-stage process characterization, process validation, method validation, and technology transfer activities
  • Microbiology Laboratory equipped for rapid sterility testing, accelerating critical release timelines for autologous therapies, while also supporting allogeneic products.
  • Expanded GMP Warehouse providing significantly increased storage capacity to support growing late-phase clinical development and commercial supply needs
  • Administrative Expansion workspaces for over 100 team members, supporting our growing organization

The expanded facility is projected to be fully operational by the end of the third quarter of 2026.

Investing in Systems That Scale

Alongside the physical build-out, Kincell Bio is making complementary investments in the digital infrastructure required to support commercial-stage operations. Further investment in the organization’s Veeva quality management system will further streamline quality operations, enhance end-to-end visibility and control, and provide the scalability necessary as an increasing number of cell therapy products advance toward and enter the commercial market. Additionally, investment in the company’s enterprise resource planning (ERP) system will support end-to-end program and product management, ensuring operational efficiency keeps pace with growing client demand.

“Cell therapy demands the best in science, process execution, and partnership,” shared Bruce Thompson, PhD, President and Chief Technology Officer. “This expansion is a direct expression of our commitment to staying at the forefront of analytical technologies, process development, and manufacturing operations. We are strengthening the infrastructure today that will deliver transformative therapies to patients tomorrow.”

About Kincell Bio

Kincell Bio engineers cells into therapies. With manufacturing facilities located in Research Triangle Park, NC, and Gainesville, FL, Kincell Bio is a contract development and manufacturing organization (CDMO) with the mission to streamline CMC development, with expertise in analytical and process development and GMP manufacturing, testing, and release from early clinical, to pivotal studies and product launch. Kincell Bio is focused on supporting innovative companies developing immune cell therapies, including autologous and allogeneic CAR-T, TCRs, Tregs, and CAR-NK programs, and on developing expertise in stem cell products and iPSCs.

For more information, visit www.kincellbio.com, and follow us on LinkedIn.

Media Contact:

Stewart McNaull, PhD
Chief Commercial Officer
Kincell Bio, Inc.
Email: stewart.mcnaull233@kincellbio.com

Research Triangle Park, NC — Kincell Bio, a leading U.S. cell therapy contract development and manufacturing organization (CDMO), today announced a new collaboration with RegCell, a biotechnology company developing first‑in‑class immune tolerance platform based on epigenetically reprogrammed regulatory T cells (Tregs). Under the partnership, Kincell Bio will provide comprehensive CMC development and GMP manufacturing support to accelerate RegCell’s lead Treg program toward clinical trial evaluation.

As part of the collaboration, RegCell will transfer its lead Treg program to Kincell Bio for process and analytical transfer and development, optimization of a scalable manufacturing process, and GMP clinical material supply to support IND‑enabling activities and clinical trials.  The collaboration is designed to streamline development timelines and ensure robust clinical supply for RegCell’s novel epigenetic reprogramming platform, aligning closely with Kincell’s mission to accelerate CMC development and clinical manufacturing for cell therapy innovators.

RegCell’s platform converts disease-driving CD4+ T cells into lineage-stable, antigen-matched Tregs by recapitulating critical epigenetic features involved in Treg imprinting and stability.  RegCell was founded by Professor Shimon Sakaguchi,  Distinguished Professor of Osaka University, Professor Emeritus of Kyoto University, who shared the 2025 Nobel Prize for Physiology or Medicine for his contributions to understanding immune tolerance and the role of Tregs.  Notably, RegCell’s platform does not require gene editing or viral DNA reagents, substantially reducing manufacturing complexity and enabling automation and potential point-of-care access. 

“Our relationship with Kincell Bio is a critical part of our US strategic plan and enables us to access leading capabilities in T-cell manufacturing, as well as to focus on creating a commercially viable manufacturing process at an early stage of clinical development,” said Michael McCullar, Ph.D., Chief Executive Officer of RegCell. 

“I’m excited for Kincell Bio to support RegCell as they advance a deeply innovative therapeutic approach rooted in decades of foundational immunology,” said Bruce Thompson, PhD, President and Chief Technology Officer of Kincell Bio. “RegCell’s science represents a significant advancement in the treatment of autoimmune disorders, and our team is committed to providing the technical solutions and GMP execution required for clinical success.”

Kincell excels at CMC development and clinical supply for innovators by providing industry-leading process and analytical development, and early clinical and late-stage clinical cGMP manufacturing capabilities that are serving the needs of biotech and pharmaceutical companies.  Kincell is committed to advancing the field of cell therapy with tailored solutions that empower innovators to bring their therapies to market efficiently and effectively.

“We are proud to partner with RegCell in advancing this groundbreaking new category of cell therapy,” said Larry Pitcher, Chief Executive Officer at Kincell Bio. “RegCell’s vision for restoring immune tolerance through precisely engineered Tregs aligns perfectly with Kincell’s mission to empower pioneering cell therapy developers with agile, reliable, and high‑quality CMC and manufacturing support.”

About Kincell Bio

Kincell Bio engineers cells into therapies. With manufacturing facilities located in Research Triangle Park, NC, and Gainesville, FL, Kincell Bio is a contract development and manufacturing organization (CDMO) with the mission to streamline CMC development, with expertise in analytical and process development and GMP manufacturing, testing and release from early clinical, to pivotal studies, and product launch. Kincell Bio is focused on supporting innovative companies developing immune cell therapies, including autologous and allogeneic CAR-T, TCRs, Tregs, and CAR-NK programs, as well as developing expertise in stem cell products and iPSCs.

For more information, visit www.kincellbio.com, and follow us on LinkedIn.

About RegCell

RegCell is a global biotechnology company based in the U.S. and built on the pioneering discoveries of Co-Founder Professor Shimon Sakaguchi in regulatory T-cell biology. RegCell is pioneering cell therapies for autoimmune diseases and transplantation, with a first indication in autoimmune hepatitis. RegCell has developed a best-in-class proprietary platform to generate stable, epigenetically reprogrammed, antigen-specific Tregs to restore antigen-specific immune tolerance. By addressing unknown or multiple pathogenic antigens, RegCell’s platform addresses key limitations that have thus far prevented the development of cell therapies for unmet needs in autoimmune diseases, which are typically managed with drugs that broadly suppress the immune system rather than target the underlying cause. RegCell’s approach does not require genetic modifications, allowing for simplified manufacturing, enhanced safety, and expanded scalability to address a broad spectrum of autoimmune patients. Driven by a vision to redefine self-tolerance, RegCell is committed to delivering safe, life-changing cell therapies that can reverse autoimmune disorders and overcome challenges in transplantation.

For more information, visit http://www.regcellbio.com/ and follow us on LinkedIn and Twitter.

Media Contact:

Ignacio Guerrero-Ros, Ph.D., or Tierney Sovic, MSc
Russo Partners LLC
ignacio.guerrero-ros@russopartnersllc.com
tierney.sovic@russopartnersllc.com

Follow a manual added link

Quality First

Follow a manual added link

 Better Science

Follow a manual added link

Reliable Supply

Follow a manual added link

 Personalized Service

Follow a manual added link

 Right Scale

1622 NW 55th Place
Gainesville, FL 32653

20 TW Alexander Dr, Suite 130
RTP, NC 27713

contactus@kincellbio.com

linkedin Icon

Phases Supported

Services

Modalities Supported

© 2026 Kincell Bio. Terms of Service | Privacy Policy | Cookie Policy | Accessibility Statement